Market diffusion of biosimilars in off-patent biologic drug markets across Europe

Anna-Katharina Böhm, Isa Maria Steiner and Tom Stargardt

Health Policy, 2023, vol. 132, issue C

Abstract: Biologics are among the most expensive pharmaceuticals but have begun to lose their exclusivity rights over the past 15 years, offering the possibility for biosimilar competition. Therefore, we examine the market diffusion of biosimilars across Europe.

Keywords: Biosimilar competition; Market diffusion; Biologics patent expiry; Biosimilar market shares; Loss of exclusivity (search for similar items in EconPapers)
Date: 2023
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
http://www.sciencedirect.com/science/article/pii/S0168851023001033
Full text for ScienceDirect subscribers only

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:eee:hepoli:v:132:y:2023:i:c:s0168851023001033

DOI: 10.1016/j.healthpol.2023.104818

Access Statistics for this article

Health Policy is currently edited by Katrien Kesteloot, Mia Defever and Irina Cleemput

More articles in Health Policy from Elsevier
Bibliographic data for series maintained by Catherine Liu () and ().